A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome

Trial Profile

A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Malignant carcinoid syndrome; Neuroendocrine tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms ELECT
  • Sponsors Ipsen Biopharmaceuticals; Ipsen Pharma SA
  • Most Recent Events

    • 18 Sep 2017 According to an Ipsen media release, based on the data from this study, the U.S. Food and Drug Administration (FDA) has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results assessing effect of previous treatment with Octreotide on efficacy of Lanreotide depot against carcinoid syndrome symptoms, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top